**Abstract**

Transcatheter percutaneous pulmonary valve implantation (PPVI) was first described in 2000 by Philip Bonhoeffer et al 1 as an alternative to open-heart surgery to prolong survival of a right ventricular outflow tract (RVOT) valve conduit. Since then multiple studies have documented the short term benefits of PPVI implantation using the Melody™ valved stent (Medtronic Inc, Minneapolis, USA) for dysfunctional right ventricle to pulmonary artery (RV-AP) conduits.

This review discusses the development, current status and future endeavors of the Melody valve in the pulmonic position.

**Key Words**

Pulmonic valve therapy • Melody valve

**Conflict of Interest**

The author is proctor for Medtronic, Edwards, NuMed.

**References**


Cite this article as: Gewillig M. Current Status of Percutaneous Pulmonic Valve Therapies: The Melody Valve. Journal of Structural Heart Disease 2015;1(2):33-34. DOI: http://dx.doi.org/10.12945/j.shjd.2015.012.14